Federico Buersgens
Co-founder & CEO, Amplifold
Federico Buersgens is listed as Co-founder & CEO, Amplifold. Federico spoke at Slush 2026 in November 2026. Federico is scheduled to speak at Slush 2026 on 19 November 2026.
Compiled from published conference agendas; not yet confirmed by Federico. Is this you? Claim this profile.
About
Dr. Federico Buersgens is a serial diagnostics entrepreneur and Co-Founder & CEO of Amplifold, a Munich-based startup developing a next-generation lateral flow assay for ultra-sensitive cardiac Troponin I detection at the point of care. Its CE-IVDR certified platform aims to bring hospital-grade cardiac biomarker testing into primary care. Federico holds a PhD in physics from LMU Munich and co-founded GNA Biosolutions, an LMU spin-off he grew from a university lab in 2010 into a molecular diagnostics platform that raised over $40M and was acquired by Hewlett Packard in 2021. He then served as Global Head of R&D for HP Health Solutions and Managing Director of its German entity. With Amplifold, he is applying that playbook to a new frontier in cardiac diagnostics.
Upcoming
Slush 2026 18 November 2026 – 19 November 2026
- Therapeutics & Diagnostics Speaker · 19 November 2026
Sessions at 1 conference
Slush 2026 18 November 2026 – 19 November 2026
Announced as a speaker.
Spoke alongside
People who have shared a session with Federico at events on B2DB.
- Brad Treeby Co-founder & CEO · NeuroHarmonics 1 shared session
- David Hardwicke Co-founder & Director, Head of BD · Aerska 1 shared session
- Simon Romanski Co-founder & CEO · Atlas.bio 1 shared session